Ovid Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	1.58	7.25	0.57	0.39	1.5	208.38
Revenue Growth	-76.20%	1181.27%	44.39%	-73.91%	-99.28%	1551.57%
Gross Profit	1.58	7.25	0.57	0.39	1.5	208.38
Selling, General & Admin	26.05	24.11	23.88	29.59	32.43	37.23
Research & Development	33.6	25.58	35.07	28.39	24.62	46.94
Operating Expenses	59.64	49.69	58.95	57.97	57.05	84.17
Operating Income	-58.06	-42.44	-58.39	-57.58	-55.55	124.21
Interest & Investment Income	3.45	2.03	3.92	-	-	-
Other Non Operating Income (Expenses)	-0.63	0.15	30	4.94	1.83	-0.05
EBT Excluding Unusual Items	-55.24	-40.27	-24.47	-52.64	-53.71	124.16
Merger & Restructuring Charges	-	-	-3.5	-1.7	-	-
Gain (Loss) on Sale of Investments	21.05	21.05	3.34	2	-0.45	-
Other Unusual Items	-0.3	1.8	-1.8	-	-	-
Pretax Income	-34.49	-17.41	-26.43	-52.34	-54.17	124.16
Income Tax Expense	-	-	-	-	-	1.33
Net Income	-34.49	-17.41	-26.43	-52.34	-54.17	122.83
Preferred Dividends & Other Adjustments	-0.01	-0.27	-0.46	-0.91	-	3
Net Income to Common	-34.48	-17.14	-25.98	-51.43	-54.17	119.84
Net Income Growth	-	-	-	-	-	-
Shares Outstanding (Basic)	122	74	71	71	70	67
Shares Outstanding (Diluted)	122	74	71	71	70	68
Shares Change	71.09%	3.99%	0.46%	0.22%	3.46%	16.45%
EPS (Basic)	-0.28	-0.23	-0.37	-0.73	-0.77	1.78
EPS (Diluted)	-0.28	-0.23	-0.37	-0.73	-0.77	1.76
EPS Growth	-	-	-	-	-	-
Free Cash Flow	-54.77	-38.33	-56.03	-45.82	-56.45	118.43
Free Cash Flow Per Share	-0.45	-0.52	-0.79	-0.65	-0.80	1.74
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Operating Margin	-3667.59%	-585.20%	-10315.37%	-14689.03%	-3696.44%	59.61%
Profit Margin	-2177.95%	-236.38%	-4589.22%	-13119.39%	-3604.66%	57.51%
Free Cash Flow Margin	-3460.08%	-528.60%	-9898.76%	-11689.03%	-3756.55%	56.83%
EBITDA	-57.97	-42.17	-57.77	-57.01	-55.04	124.45
EBITDA Margin	-	-	-	-	-	59.72%
D&A For EBITDA	0.08	0.27	0.61	0.57	0.51	0.24
EBIT	-58.06	-42.44	-58.39	-57.58	-55.55	124.21
EBIT Margin	-	-	-	-	-	59.61%
Effective Tax Rate	-	-	-	-	-	1.07%
Revenue as Reported	1.58	7.25	0.57	0.39	1.5	208.38

SEC Filings: 10-K · 10-Q